{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:11:59Z","timestamp":1762521119687},"reference-count":47,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We studied the association between HLA alleles and rubella-specific gamma interferon (IFN-\u03b3) (Th1) and interleukin-10 (IL-10) (Th2) cytokine responses among 106 healthy children (ages, 14 to 17 years) previously immunized with two doses of rubella vaccine. Antibody titers and cytokine responses to rubella vaccination were not sex or age dependent. Several class I HLA-A (*0201, *2402, *6801) alleles were significantly associated with rubella vaccine-induced IFN-\u03b3 secretion. Several class II HLA-DRB1 (*0101) and HLA-DQB1 (*0501) alleles were also suggestive of an association with IFN-\u03b3 secretion. Alleles with potential associations with rubella-specific IL-10 production included HLA-A (*0201, *6801), HLA-B (*4901), and HLA-DRB1 (*1302). The class I A*0201 and A*6801 alleles were associated with both IFN-\u03b3 and IL-10 secretion. These tentative associations need to be validated in larger studies with subjects of differing ethnicities. These results provide additional evidence that HLA genes may influence Th1- and Th2-specific cytokine response(s) following rubella immunization, which in turn can influence both cellular and humoral immune responses to rubella vaccination.<\/jats:p>","DOI":"10.1128\/cvi.00247-06","type":"journal-article","created":{"date-parts":[[2007,1,11]],"date-time":"2007-01-11T01:39:00Z","timestamp":1168479540000},"page":"115-122","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":28,"title":["Relationship between HLA Polymorphisms and Gamma Interferon and Interleukin-10 Cytokine Production in Healthy Individuals after Rubella Vaccination"],"prefix":"10.1128","volume":"14","author":[{"given":"Inna G.","family":"Ovsyannikova","sequence":"first","affiliation":[{"name":"Mayo Vaccine Research Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Mayo Vaccine Research Group"},{"name":"Department of Pediatric and Adolescent Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna E.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Mayo Vaccine Research Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Dhiman","sequence":"additional","affiliation":[{"name":"Mayo Vaccine Research Group"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Vierkant","sequence":"additional","affiliation":[{"name":"Division of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[{"name":"Mayo Vaccine Research Group"},{"name":"Program in Translational Immunovirology and Biodefense"},{"name":"Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/00365540152029945","volume":"33","year":"2001","unstructured":"Akaboshi, I., I. Nagayoshi, M. Omura, and K. Iwaki. 2001. Elevated serum levels of interleukin-10 in children with acute rubella infection. Scand. J. Infect. Dis.33:462-465.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1017\/S0950268899004173","volume":"125","year":"2000","unstructured":"Andrews, N., R. G. Pebody, G. Berbers, C. Blondeau, P. Crovari, I. Davidkin, P. Farrington, F. Fievet-Groyne, G. Gabutti, E. Gerike, C. Giordano, L. Hesketh, T. Marzec, P. Morgan, K. Capner, K. Osborne, A. M. Pleisner, M. Raux, A. Tischer, U. Ruden, M. Valle, and E. Miller. 2000. The European sero-epidemiology network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiol. Infect.125:127-143.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1086\/497607","volume":"192","year":"2005","unstructured":"Best, J. M., C. Castillo-Solorzano, J. S. Spika, J. Icenogle, J. W. Glasser, N. J. Gay, J. Andrus, and A. M. Arvin. 2005. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization steering committee on research related to measles and rubella vaccines and vaccination, June 2004. J. Infect. Dis.192:1890-1897.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0091-6749(98)70238-6","volume":"101","year":"1998","unstructured":"Borish, L. 1998. IL-10: evolving concepts. J. Allergy Clin. Immunol.101:293-297.","journal-title":"J. Allergy Clin. Immunol."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0264-410X(95)00098-L","volume":"13","year":"1995","unstructured":"Boulianne, N., G. De Serres, S. Ratnam, B. J. Ward, J. R. Joly, and B. Duval. 1995. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine13:1611-1616.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/08916939409007985","volume":"18","year":"1994","unstructured":"Candore, G., D. Cigna, F. Gervasi, A. T. Colucci, M. A. Modica, and C. Caruso. 1994. In vitro cytokine production by HLA-B8, DR3 positive subjects. Autoimmunity18:121-132.","journal-title":"Autoimmunity"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/jir.1996.16.983","volume":"16","year":"1996","unstructured":"Caruso, C., G. Candore, M. A. Modica, C. T. Bonanno, G. Sireci, F. Dieli, and A. Salerno. 1996. Major histocompatibility complex regulation of cytokine production. J. Interferon Cytokine Res.16:983-988.","journal-title":"J. Interferon Cytokine Res."},{"key":"e_1_3_2_9_2","first-page":"391","volume":"43","year":"1994","unstructured":"Centers for Disease Control and Prevention. 1994. Rubella and congenital rubella syndrome\u2014United States, January 1, 1991-May 7, 1994. Morb. Mortal. Wkly. Rep.43:391-401.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_10_2","first-page":"1247","volume":"46","year":"1998","unstructured":"Centers for Disease Control and Prevention. 1998. Rubella among crew members of commercial cruise ships\u2014Florida, 1997. Morb. Mortal. Wkly. Rep.46:1247-1250.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1001\/jama.1988.03720210023022","volume":"259","year":"1988","unstructured":"Chu, S. Y., R. H. Bernier, J. A. Stewart, K. L. Herrmann, J. R. Greenspan, A. K. Henderson, and A. P. Liang. 1988. Rubella antibody persistence after immunization. Sixteen-year follow-up in the Hawaiian Islands. JAMA259:3133-3166.","journal-title":"JAMA"},{"key":"e_1_3_2_12_2","first-page":"55","volume":"75","year":"1997","unstructured":"Cutts, F. T., S. E. Robertson, J.-L. Diaz-Ortega, and R. Samuel. 1997. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull. W. H. O.75:55-68.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2105\/AJPH.93.2.289","volume":"93","year":"2003","unstructured":"Danovaro-Holliday, M. C., E. R. Gordon, C. Woernle, G. H. Higginbotham, R. H. Judy, J. P. Icenogle, and S. E. Reef. 2003. Identifying risk factors for rubella susceptibility in a population at risk in the United States. Am. J. Public Health93:289-291.","journal-title":"Am. J. Public Health"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4049\/jimmunol.150.2.353","volume":"150","year":"1993","unstructured":"Del Prete, G., M. de Carli, F. Almerigogna, M. G. Giudizi, R. Biagiotti, and S. Romagnani. 1993. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol.150:353-360.","journal-title":"J. Immunol."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clim.2004.12.010","volume":"115","year":"2005","unstructured":"Dhiman, N., I. G. Ovsyannikova, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children. Clin. Immunol.115:154-161.","journal-title":"Clin. Immunol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2249.2005.02931.x","volume":"142","year":"2005","unstructured":"Dhiman, N., I. G. Ovsyannikova, J. E. Ryan, R. M. Jacobson, R. A. Vierkant, S. V. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. Correlations among measles virus-specific antibody, lymphoproliferation and Th1\/Th2 cytokine responses following MMR-II vaccination. Clin. Exp. Immunol.142:498-504.","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3476(78)80064-X","volume":"92","year":"1978","unstructured":"Fogel, A., C. B. Gerichter, B. Barnea, R. Handsher, and E. Heeger. 1978. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatr.92:26-29.","journal-title":"J. Pediatr."},{"key":"e_1_3_2_18_2","first-page":"258","volume":"29","year":"1975","unstructured":"Freestone, D. S., G. M. Reynolds, J. A. McKinnon, and J. Prydie. 1975. Vaccination of schoolgirls against rubella. Br. J. Prev. Soc. Med.29:258-261.","journal-title":"Br. J. Prev. Soc. Med."},{"key":"e_1_3_2_19_2","first-page":"864","volume":"854","year":"1993","unstructured":"Frey, T. K., and E. S. Abernathy. 1993. Identification of strain-specific nucleotide sequences in the RA 27\/3 rubella virus vaccine. J. Infect. Dis.854:864.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-81-10-2341"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00006454-198307000-00005","volume":"2","year":"1983","unstructured":"Greaves, W. L., W. A. Orenstein, A. R. Hinman, and W. S. Nersesian. 1983. Clinical efficacy of rubella vaccine. Pediatr. Infect. Dis.2:284-286.","journal-title":"Pediatr. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/inf.1975.7.issue-3.03","volume":"7","year":"1975","unstructured":"Grillner, L. 1975. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand. J. Infect. Dis.7:169-172.","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM200009073431006","volume":"343","year":"2000","unstructured":"Klein, J., and A. Sato. 2000. The HLA system. First of two parts. N. Engl. J. Med.343:702-709.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJM200009143431106","volume":"343","year":"2000","unstructured":"Klein, J., and A. Sato. 2000. The HLA system. Second of two parts. N. Engl. J. Med.343:782-786.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_25_2","first-page":"217","volume":"3","year":"1997","unstructured":"Lio, D., G. Candore, G. C. Romano, C. D'Anna, F. Gervasi, G. Di Lorenzo, M. A. Modica, M. Potestio, and C. Caruso. 1997. Modification of cytokine patterns in subjects bearing the HLA-B8, DR3 phenotype: implications for autoimmunity. Cytokines Cell. Mol. Ther.3:217-224.","journal-title":"Cytokines Cell. Mol. Ther."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/S0264-410X(99)00040-7","volume":"17","year":"1999","unstructured":"Mitchell, L. A., A. J. Tingle, D. D\u00e9carie, and R. Shukin. 1999. Identification of rubella virus T-cell epitopes recognized in anamnestic response to RA27\/3 vaccine: associations with boost in neutralizing antibody titer. Vaccine17:2356-2365.","journal-title":"Vaccine"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/513807","volume":"177","year":"1998","unstructured":"Mitchell, L. A., A. J. Tingle, L. MacWilliam, C. Horne, P. Keown, L. K. Gaur, and G. T. Nepom. 1998. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J. Infect. Dis.177:5-12.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0065-2776(08)60652-5","volume":"46","year":"1989","unstructured":"Mosmann, T. R., and R. L. Coffman. 1989. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol.46:111-147.","journal-title":"Adv. Immunol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","volume":"7","year":"1989","unstructured":"Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol.7:145-173.","journal-title":"Annu. Rev. Immunol."},{"key":"e_1_3_2_30_2","first-page":"187","volume":"61","year":"1988","unstructured":"Nakayama, T., T. Urano, M. Osano, M. Nakagawa, N. Maehara, K. Sasaki, and S. Makino. 1988. Production of interferon by human peripheral lymphocytes stimulated with rubella virus. Kitasato Arch. Exp. Med.61:187-193.","journal-title":"Kitasato Arch. Exp. Med."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/424571","volume":"190","year":"2004","unstructured":"Naniche, D., M. Garenne, C. Rae, M. Manchester, R. Buchta, S. K. Brodine, and M. B. Oldstone. 2004. Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J. Infect. Dis.190:1387-1395.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_32_2","first-page":"75","volume":"65","year":"1986","unstructured":"Orenstein, W. A., K. Herrmann, P. Albrecht, R. Bernier, P. Holmgreen, K. J. Bart, and A. R. Hinman. 1986. Immunity against measles and rubella in Massachusetts schoolchildren. Dev. Biol. Stand.65:75-83.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.285.6337.253","volume":"285","year":"1982","unstructured":"O'Shea, S., J. M. Best, J. E. Banatvala, W. C. Marshall, and J. A. Dudgeon. 1982. Rubella vaccination: persistence of antibodies for up to 16 years. Br. J. Med.285:253-255.","journal-title":"Br. J. Med."},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00251-004-0756-0","volume":"56","year":"2005","unstructured":"Ovsyannikova, I. G., R. M. Jacobson, J. E. Ryan, R. A. Vierkant, V. S. Pankratz, S. J. Jacobsen, and G. A. Poland. 2005. HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine. Immunogenetics56:798-807.","journal-title":"Immunogenetics"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.humimm.2004.07.001","volume":"65","year":"2004","unstructured":"Ovsyannikova, I. G., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, V. S. Pankratz, and G. A. Poland. 2004. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum. Immunol.65:1506-1515.","journal-title":"Hum. Immunol."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1086\/427558","volume":"191","year":"2005","unstructured":"Ovsyannikova, I. G., R. M. Jacobson, R. A. Vierkant, S. J. Jacobsen, V. S. Pankratz, and G. A. Poland. 2005. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J. Infect. Dis.191:515-519.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_37_2","unstructured":"Ovsyannikova I. G. R. M. Jacobson N. Dhiman J. E. Ryan N. A. Pinsky R. A. Vierkant and G. A. Poland. 2005. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. abstr. G-843."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-3083.1998.00435.x","volume":"48","year":"1998","unstructured":"Paludan, S. R. 1998. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand. J. Immunol.48:459-468.","journal-title":"Scand. J. Immunol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/clinids\/7.Supplement_1.S73","volume":"7","year":"1985","unstructured":"Perkins, F. T. 1985. Licensed vaccines. Rev. Infect. Dis.7(Suppl. 1):S73-S76.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/S0264-410X(01)00073-1","volume":"19","year":"2001","unstructured":"Plotkin, S. A. 2001. Rubella eradication. Vaccine19:3311-3319.","journal-title":"Vaccine"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.inf.0000145549.02777.5d","volume":"23","year":"2004","unstructured":"Plotkin, S. A. 2004. Commentary: congenital rubella syndrome should not be a disease of poor countries. Pediatr. Infect. Dis. J.23:1123-1124.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jama.1973.03220330013003","volume":"225","year":"1973","unstructured":"Plotkin, S. A., J. D. Farquhar, and P. L. Ogra. 1973. Immunologic properties of RA27\/3 rubella virus vaccine. JAMA225:585-590.","journal-title":"JAMA"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00008480-199804000-00017","volume":"10","year":"1998","unstructured":"Poland, G. A., and R. M. Jacobson. 1998. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr.10:208-215.","journal-title":"Curr. Opin. Pediatr."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/09629350310001599639","volume":"12","year":"2003","unstructured":"Pukhalsky, A. L., G. V. Shmarina, M. S. Bliacher, I. M. Fedorova, A. P. Toptygina, J. J. Fisenko, and V. A. Alioshkin. 2003. Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediat. Inflamm.12:203-207.","journal-title":"Mediat. Inflamm."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.287.4.464","volume":"287","year":"2002","unstructured":"Reef, S. E., T. K. Frey, K. Theall, E. Abernathy, C. L. Burnett, J. Icenogle, M. M. McCauley, and M. Wharton. 2002. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA287:464-472.","journal-title":"JAMA"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.27.2.309-314.1980"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3181\/00379727-165-40931","volume":"165","year":"1980","unstructured":"Weibel, R. E., V. M. Villarejos, E. B. Klein, E. B. Buynak, A. A. McLean, and M. R. Hilleman. 1980. Clinical and laboratory studies of live attenuated RA 27\/3 and HPV 77-DE rubella virus vaccines. Proc. Soc. Exp. Biol. Med.165:44-49.","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0163-7258(90)90012-Q","volume":"45","year":"1990","unstructured":"Young, H. A., and K. J. Hardy. 1990. Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation. Pharmacol. Ther.45:137-151.","journal-title":"Pharmacol. Ther."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00247-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00247-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T09:57:14Z","timestamp":1683712634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00247-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1128\/CVI.00247-06"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00247-06","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"2006-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}